Business
Natural Alternatives International, Inc. Announces 2026 Q1 Results
CARLSBAD, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $0.3 million, or $0.05 per diluted share, on net sales of $37.7 million for the first quarter of fiscal year 2026 compared to a net loss of $2.0 million, or $0.33 per diluted share, in the first quarter of the prior fiscal year. Net sales during the three months en
About this update from Natural Alternatives International, Inc.
[{"type":"image","alt":"Natural Alternatives International Inc","displaySize":"","headline":null,"caption":"Natural Alternatives International Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/4f3e1356662d6b44cb17ad390e90dedf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jD6TFBV9nBhhlhndwfuCdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4f3e1356662d6b44cb17ad390e90dedf","width":300,"height":108}},"lazy":false},{"type":"text","content":"CARLSBAD, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $0.3 million, or $0.05 per diluted share, on net sales of $37.7 million for the first quarter of fiscal year 2026 compared to a net loss of $2.0 million, or $0.33 per diluted share, in the first quarter of the prior fiscal year.","length":473,"tagName":"p"},{"type":"text","content":"Net sales during the three months ended September 30, 2025, increased $4.6 million, or 13.8%, to $37.7 million as compared to $33.2 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased $5.4 million, a 17.7% increase from the comparable quarter last year. Private-label contract manufacturing sales increased primarily due to increased orders from several of our existing customers and shipments to new customers.","length":490,"tagName":"p"},{"type":"text","content":"CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 33.9% to $1.7 million during the first quarter of fiscal year 2026, as compared to $2.5 million for the first quarter of fiscal year 2025. The decrease in patent and trademark licensing revenue during the first quarter of fiscal 2026 was primarily due to decreased raw material orders from existing customers, partially offset by sales of our new TriBsyn™ product and increased royalty and licensing revenue.","length":496,"tagName":"p"},{"type":"text","content":"We generated income from operations during the first quarter of fiscal 2026 as compared to a loss from operations during the first quarter of fiscal 2025. The improvement...